MDM2 Promoter Polymorphism and Pancreatic Cancer Risk and Prognosis
-
2008/06/15
-
Details
-
Personal Author:Asomaning K ; Blaszkowsky L ; Christiani, David C. ; Heist RS ; Kwak EL ; Liu G ; Reid AE ; Ryan DP ; Su L ; Zhai R ; Zhou W ; Zhu AX
-
Description:Purpose: The mouse double minute 2 homologue (MDM2) -309T/G promoter polymorphism has been associated recently with the development and prognosis of a variety of tumors. The G allele is associated with increased affinity for Sp1 binding and higher MDM2 mRNA and protein levels, leading to diminished tumor suppressor activity of the p53 pathway. We hypothesized that the G allele is also associated with increased risk and worse outcome in pancreatic cancer. Experimental design: We evaluated the association between MDM2 309T/G and the risk of histologically confirmed pancreatic adenocarcinoma at Massachusetts General Hospital using unconditional logistic regression (123 cases and 372 controls). Complete overall survival and progression-free survival data were also available for 109 newly diagnosed patients. Results: The adjusted odds ratios (95% confidence intervals) of pancreatic cancer associated with the MDM2 T/G and G/G genotypes compared with TT were 1.89 (1.20-2.99) and 2.07 (1.03-4.16), respectively (adjusting for age, gender, smoking status, and pack-years of smoking). In Cox proportional hazards model with the wild-type T/T genotype as the reference category and adjusting for stage, treatment, and performance status, both the heterozygous T/G and the homozygous G/G genotypes were associated with decreased progression-free survival [adjusted hazard ratio (95% confidence interval), 1.67 (0.98-2.84) for T/G and 2.28 (1.11-4.71) for G/G] and overall survival [2.64 (1.23-5.67) for T/G and 3.12 (1.22-7.91) for G/G]. Conclusions: The G allele of the MDM2 -309T/G polymorphism is associated with 2- to 3-fold increase risk and progression of pancreatic adenocarcinoma and a corresponding decrease in survival. [Description provided by NIOSH]
-
Subjects:
-
Keywords:
-
ISSN:1078-0432
-
Document Type:
-
Funding:
-
Genre:
-
Place as Subject:
-
CIO:
-
Topic:
-
Location:
-
Volume:14
-
Issue:12
-
NIOSHTIC Number:nn:20060033
-
Citation:Clin Cancer Res 2008 Jun; 14(12):4010-4015
-
Contact Point Address:Geoffrey Liu, 610 UniversityAvenue, Room 7-124,Toronto, Ontario, Canada M5G-2M9
-
Email:Geoffrey.Liu@uhn.on.ca
-
Federal Fiscal Year:2008
-
Performing Organization:Harvard School of Public Health
-
Peer Reviewed:True
-
Start Date:20050701
-
Source Full Name:Clinical Cancer Research
-
End Date:20280630
-
Collection(s):
-
Main Document Checksum:urn:sha-512:e00b6a28fef9f5e2f0f58d5a37fcc03311776ed5a8b307e92f0beae105a1f6a426399c0f1f72f19bb15990866a1a9e3b45a01c5429dc54fb9b8356a97bf63dc7
-
Download URL:
-
File Type:
ON THIS PAGE
CDC STACKS serves as an archival repository of CDC-published products including
scientific findings,
journal articles, guidelines, recommendations, or other public health information authored or
co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
You May Also Like